Public Market Listing
600276SSE
Live quotes, historical charts, and market capitalization for Jiangsu Hengrui Pharmaceuticals are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(56 total)
56Total Assets
0Approved
26Phase 3 / Filed
30Phase 1–2 / Early
17Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | PD-L1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGFR2Small molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | PD-1Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | PD-1 (camrelizumab) plus VEGFR2/PDGFR-β/c-Kit (famitinib)Combination | Non-Small Cell Lung Cancer | |
| Phase 3 | CDK4 and CDK6Small molecule | Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3Small molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | Sodium-glucose cotransporter 2 (SGLT2) · DPP-4Small molecule | Type 2 Diabetes | |
| Phase 3 | Insulin receptor / GLP-1 receptor (combination)Peptide | Type 2 Diabetes | |
| Phase 3 | Central dopamine precursor (levodopa) and peripheral decarboxylase inhibitor (carbidopa/benserazide)Small molecule | Parkinson's Disease | |
| Phase 3 | GLP-1 receptorSmall molecule | ObesityType 2 DiabetesHypertensionHeart Failure | |
| Phase 3 | Insulin receptor (basal)Peptide | Type 2 Diabetes | |
| Phase 3 | GLP-1 receptorPeptide | Type 2 Diabetes | |
| Phase 3 | GLP-1 receptorPeptide | Type 2 Diabetes | |
| Phase 3 | EGFR/HER1, HER2, HER4Small molecule | Non-Small Cell Lung Cancer | |
| Phase 3 | PCSK9Monoclonal antibody | Atherosclerotic Cardiovascular Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.